Galmed Announces ARRIVE Study Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
H.C. Wainwright Remains Bullish on Galmed Pharma (GLMD) Followng Sell Off
February 15, 2018 8:58 AM ESTH.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that the ARRIVE study did not meet its primary endpoint of improvement in liver fat at 12 weeks. Shares closed at $5.45, down -42.4%, after recovering somewhat... More
H.C. Wainwright Remains Bullish on Galmed Pharma (GLMD) Followng Sell Off
February 15, 2018 8:58 AM ESTH.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that the ARRIVE study did not meet its primary endpoint of improvement in liver fat at 12 weeks. Shares closed at $5.45, down -42.4%, after recovering somewhat... More
